Fairmount Funds Management LLC holds a concentrated book of 12 stocks worth $1.4B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Damora Therapeutics Inc and trimmed Cogent Biosciences Inc. Their largest long position is Damora Therapeutics Inc at 16% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1802528/holdings"
Use Arkolith to show Fairmount Funds Management LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Damora Therapeutics Inc COM NEW | $225.7M | 8.71M | 16.3% | ▲New New position | |
| 2 | Dianthus Therapeutics Inc COM | $212.9M | 2.54M | 15.4% | ▲+19% Added · +400K sh | |
| 3 | Cogent Biosciences Inc COM | $211.8M | 5.50M | 15.3% | ▼−39% Reduced · −3.5M sh | |
| 4 | Spyre Therapeutics Inc COM NEW | $202.7M | 4.02M | 14.6% | —Held | |
| 5 | Oruka Therapeutics Inc COM | $181.7M | 3.71M | 13.1% | —Held | |
| 6 | Viridian Therapeutics Inc COM | $76.6M | 3.91M | 5.5% | —Held | |
| 7 | Enliven Therapeutics Inc COM | $72.7M | 1.86M | 5.3% | ▼−50% Reduced · −1.9M sh | |
| 8 | Jade Biosciences Inc COM NEW | $64.0M | 4.55M | 4.6% | —Held | |
| 9 | Crescent Biopharma Inc. COM | $50.5M | 2.75M | 3.6% | —Held | |
| 10 | Zenas Biopharma Inc COM | $46.1M | 2.36M | 3.3% | ▲+6.8% Added · +150K sh | |
| 11 | Apogee Therapeutics Inc COM | $25.1M | 298.6K | 1.8% | ▼−85% Reduced · −1.8M sh | |
| 12 | Inhibikase Therapeutics Inc COM NEW | $14.5M | 8.63M | 1.0% | —Held |
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.